RNAi-mediated COPS3 gene silencing inhibits metastasis of osteogenic sarcoma cells

Cancer Gene Therapy

Volumn 18, Issue 6, 2011, Pages 450-456

  Yan, T ^a   Tang, G ^a   Ren, T ^a   Shen, D ^a   Sun, K ^a   Liang, W ^a   Guo, W ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

COPS3; immunostaining; metastasis; osteogenic sarcoma; siRNA

Indexed keywords

BETA ACTIN; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER MORTALITY; CANCER PATIENT; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; COPS3 GENE; DOWN REGULATION; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS INHIBITION; OSTEOSARCOMA; PRIORITY JOURNAL; RNA INTERFERENCE; SARCOMA CELL; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 79956098940     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.16     Document Type: Article

References (32)

1. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop 2002; 397: 40-52. (Pubitemid 34442014)
2. Jaffe N, Carrasco H, Raymond K, Ayala A, Eftekhari F. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer 2002; 10: 2202-2210. (Pubitemid 35253383)
3. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K et al. Prognostic factors in high-grade osteosar-coma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790. (Pubitemid 34111386)
4. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 1997; 44: 973-989. (Pubitemid 27368674)
5. Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003; 98: 2447-2456. (Pubitemid 37466660)
6. Bacci G, Bertoni F, Longhi A, Ferrari S, Forni C, Biagini R et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic sub-type of the tumor. Cancer 2003; 97: 3068-3075. (Pubitemid 36676262)
7. Bogenrieder T, Herlyn M. Axis of evil: molecular mechan-isms of cancer metastasis. Oncogene 2003; 22: 6524-6526.
8. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002; 12: 89-96. (Pubitemid 34680737)
9. Srivastava A, Fuchs B, Zhang K, Ruan M, Halder C, KristinWeber E et al. High wt1 expression is associated with very poor survival of patients with osteogenic sarcoma metastasis. Clin Cancer Res 2006; 12: 4237-4243.
10. Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 2008; 25: 201-211.
11. Fuchs B, Mahlum E, Halder C, Maran A, Yaszemski M, Bode B et al. High expression of tumor endothelial marker 7 is associated with metastasis and poor survival of patients with osteogenic sarcoma. Gene 2007; 399: 137-143. (Pubitemid 47211668)
12. Yang R, Hoang BH, Kubo T, Kawano H, Chou A, Sowers R et al. Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer 2007; 121: 943-954. (Pubitemid 47101629)
13. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004; 10: 182-186. (Pubitemid 38524889)
14. Tarkkanen M, Elomaa I, Blomqvist C, Kivioja AH, Kellokumpu-Lehtinen P, Bohling T et al. DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma. Int J Cancer 1999; 84: 114-121. (Pubitemid 29133820)
15. Tarkkanen M, Karhu R, Kallioniemi A, Elomaa I, Kivioja AH, Nevalainen J et al. Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res 1995; 55: 1334-1338.
16. van Dartel M, Redeker S, Bras J, Kool M, Hulsebos TJ. Overexpression through amplification of genes in chromo-some region 17p11.2 approximately p12 in high-grade osteosarcoma. Cancer Genet Cytogenet 2004; 152: 8-14. (Pubitemid 38757372)
17. Henriksen J, Aagesen TH, Maelandsmo GM, Lothe RA, Myklebost O, Forus A. Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene 2003; 22: 5358-5361. (Pubitemid 37056098)
18. Yan TQ, Wunder JS, Gokogoz N, Gill M, Eskandatian S, Parkes RK et al. COPS3 amplification and clinical outcome in osteosarcoma. Cancer 2007; 109: 1870-1876. (Pubitemid 46668553)
19. Munajat I, Zulmi W, Norazman MZ, Wan Faisham WI. Tumour volume and lung metastasis in patients with osteosarcoma. J Orthop Surg 2008; 16: 182-185.
20. Wunder JS, Gokgoz N, Parkes R, Bull SB, Eskandarian S, Davis AM et al. TP53 mutations and outcome in osteosar-coma: a prospective, multicenter study. J Clin Oncol 2005; 23: 1483-1490.
21. Wunder JS, Bull SB, Aneliunas V, Lee PD, Davis AM, Beauchamp CP et al. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 2000; 18: 2685-2694. (Pubitemid 30463550)
22. Ferrari S, Bertoni F, Mercuri M, Picci P, Giacomini S, Longhi A et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 2001; 12: 1145-1150. (Pubitemid 32834497)
23. Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003; 98: 2447-2456. (Pubitemid 37466660)
24. Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21: 2011-2018. (Pubitemid 46606391)
25. Fidler IJ. The organ microenvironment and cancer metas-tasis. Differentiation 2002b; 70: 498-505.
26. Van Dartel M, Cornelissen PWA, Redeker S, Tarkkanen M, Knuutila S, Hogendoorn PC et al. Amplification of 17p11.2Bp12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma. Cancer Genet Cytogenet 2002; 139: 91-96. (Pubitemid 36110648)
27. Lau CC, Harris CP, Lu X-Y, Perlaky L, Gogineni S, Chintagumpala M et al. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 2004; 39: 11-21. (Pubitemid 37475248)
28. Lopez-Guerrero JA, Lopez-Gines C, Pellin A, Carda C, Llombart-Bosch A. Deregulation of the G1 to S-phase cell cycle checkpoint is involved in the pathogenesis of human osteosarcoma. Diagn Mol Pathol 2004; 13: 81-91. (Pubitemid 38668143)
29. Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, Pollmann C et al. COP9 signalosome-specific phosphoryla-tion targets p53 to degradation by the ubiquitin system. EMBO J 2001; 20: 1630-1639. (Pubitemid 32299400)
30. Wei N, Deng XW. The COP9 signalosome. Annu Rev Cell Dev Biol 2003; 19: 261-266.
31. Henriksen J, Aagesen TH, Maelandsmo GM, Lothe RA, Myklebost O, Forus A. Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene 2003; 22: 5358-5361. (Pubitemid 37056098)
32. Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death and cancer. Pharmacol Rev 2008; 60: 261-310.